{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:20:52Z","timestamp":1787019652078,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,1,20]],"date-time":"2014-01-20T00:00:00Z","timestamp":1390176000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>An updated economic evaluation was conducted to compare the cost-effectiveness of the four tumour necrosis factor (TNF)-\u03b1 inhibitors adalimumab, etanercept, golimumab and infliximab in active, progressive psoriatic arthritis (PsA) where response to standard treatment has been inadequate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review was conducted to identify relevant, recently published studies and the new trial data were synthesised, via a Bayesian network meta-analysis (NMA), to estimate the relative efficacy of the TNF-\u03b1 inhibitors in terms of Psoriatic Arthritis Response Criteria (PsARC) response, Health Assessment Questionnaire (HAQ) scores and Psoriasis Area and Severity Index (PASI). A previously developed economic model was updated with the new meta-analysis results and current cost data. The model was adapted to delineate patients by PASI 50%, 75% and 90% response rates to differentiate between psoriasis outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All four licensed TNF-\u03b1 inhibitors were significantly more effective than placebo in achieving PsARC response in patients with active PsA. Adalimumab, etanercept and infliximab were significantly more effective than placebo in improving HAQ scores in patients who had achieved a PsARC response and in improving HAQ scores in PsARC non-responders. In an analysis using 1,000 model simulations, on average etanercept was the most cost-effective treatment and, at the National Institute for Health and Care Excellence willingness-to-pay threshold of between \u00a320,000 to \u00a330,000, etanercept is the preferred option.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The economic analysis agrees with the conclusions from the previous models, in that biologics are shown to be cost-effective for treating patients with active PsA compared with the conventional management strategy. In particular, etanercept is cost-effective compared with the other biologic treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/1471-2474-15-26","type":"journal-article","created":{"date-parts":[[2014,1,20]],"date-time":"2014-01-20T13:03:13Z","timestamp":1390222993000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis"],"prefix":"10.1186","volume":"15","author":[{"given":"Matthew Richard","family":"Cawson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Andrew","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Wildey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Spurden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Elaine","family":"Orme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,20]]},"reference":[{"issue":"1","key":"2010_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.5435\/JAAOS-20-01-028","volume":"20","author":"MS Day","year":"2012","unstructured":"Day MS, Nam D, Goodman S, Su EP, Figgie M: Psoriatic arthritis. J Am Acad Orthop Surg. 2012, 20 (1): 28-37. 10.5435\/JAAOS-20-01-028.","journal-title":"J Am Acad Orthop Surg"},{"issue":"3","key":"2010_CR2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/rheumatology\/ker365","volume":"51","author":"CF Rosen","year":"2012","unstructured":"Rosen CF, Mussani F, Chandran V, Eder L, Thavaneswaran A, Gladman DD: Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology (Oxford). 2012, 51 (3): 571-6. 10.1093\/rheumatology\/ker365.","journal-title":"Rheumatology (Oxford)"},{"issue":"238","key":"2010_CR3","first-page":"127","volume":"62","author":"DD Gladman","year":"1987","unstructured":"Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK: Psoriatic arthritis (PSA)\u2013an analysis of 220 patients. Q J Med. 1987, 62 (238): 127-41.","journal-title":"Q J Med"},{"issue":"4","key":"2010_CR4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/rheumatology\/30.4.245","volume":"30","author":"JC Torre Alonso","year":"1991","unstructured":"Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, Ballina Garcia J, Riestra Noriega JL, Lopez LC: Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol. 1991, 30 (4): 245-50. 10.1093\/rheumatology\/30.4.245.","journal-title":"Br J Rheumatol"},{"issue":"Suppl 2","key":"2010_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1468-3083.2009.03565.x","volume":"24","author":"S Prey","year":"2010","unstructured":"Prey S, Paul C, Bronsard V, Puzenat E, Gourraud PA, Aractingi S: Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J Eur Acad Dermatol Venereol. 2010, 24 (Suppl 2): 31-5.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"2010_CR6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/JDN.0b013e3181ba2dba","volume":"1","author":"MS Young","year":"2009","unstructured":"Young MS, Furfaro N, Rai A: Diagnosis and Management of Psoriatic Arthritis A Practical Review. Journal of the Dermatology Nurses' Association. 2009, 1 (5): 283-293. 10.1097\/JDN.0b013e3181ba2dba. 2009 September\/October","journal-title":"Journal of the Dermatology Nurses' Association"},{"issue":"9","key":"2010_CR7","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1136\/ard.2008.094946","volume":"68","author":"CT Ritchlin","year":"2009","unstructured":"Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH: Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009, 68 (9): 1387-1394. 10.1136\/ard.2008.094946. 2009 Sep","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2010_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","volume":"71","author":"L Gossec","year":"2012","unstructured":"Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D: European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012, 71 (1): 4-12. 10.1136\/annrheumdis-2011-200350.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2010_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2174\/1573397052954154","volume":"1","author":"YE Miedany","year":"2005","unstructured":"Miedany YE: Recent Developments in Management of Psoriatic Arthritis. Curr Rheumatol Rev. 2005, 1 (1): 9-19. 10.2174\/1573397052954154.","journal-title":"Curr Rheumatol Rev"},{"issue":"3","key":"2010_CR10","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/ard.2007.073544","volume":"67","author":"LE Kristensen","year":"2008","unstructured":"Kristensen LE, Gulfe A, Saxne T, Geborek P: Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis. 2008, 67 (3): 364-9.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2010_CR11","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1136\/ard.2007.085951","volume":"67","author":"A Spadaro","year":"2008","unstructured":"Spadaro A, Ceccarelli F, Scrivo R, Valesini G: Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis. Ann Rheum Dis. 2008, 67 (11): 1650-1. 10.1136\/ard.2007.085951.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2010_CR12","first-page":"883","volume":"35","author":"AA Saad","year":"2008","unstructured":"Saad AA, Symmons DP, Noyce PR, Ashcroft DM: Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol. 2008, 35 (5): 883-90.","journal-title":"J Rheumatol"},{"issue":"1","key":"2010_CR13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10067-011-1862-7","volume":"31","author":"A Migliore","year":"2012","unstructured":"Migliore A, Bizzi E, Broccoli S, Lagana B: Indirect comparison of etanercept, infliximab, and adalumimab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator. Clin Rheumatol. 2012, 31 (1): 193-4. 10.1007\/s10067-011-1862-7.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"2010_CR14","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/art.24403","volume":"60","author":"A Kavanaugh","year":"2009","unstructured":"Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J: Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009, 60 (4): 976-86. 10.1002\/art.24403.","journal-title":"Arthritis Rheum"},{"key":"2010_CR15","volume-title":"Golimumab for the treatment of psoriatic arthritis","author":"National Institute for Health and Clinical Excellence","year":"2011","unstructured":"National Institute for Health and Clinical Excellence: Golimumab for the treatment of psoriatic arthritis. 2011, London: NICE, Available from: http:\/\/www.nice.org.uk\/nicemedia\/live\/13441\/54169\/54169.pdf"},{"issue":"10","key":"2010_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta15100","volume":"15","author":"M Rodgers","year":"2011","unstructured":"Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2011, 15 (10): 1-329. February 2011","journal-title":"Health Technol Assess"},{"issue":"Suppl 4","key":"2010_CR17","doi-asserted-by":"publisher","first-page":"iv39","DOI":"10.1093\/rheumatology\/ker245","volume":"50","author":"L Bojke","year":"2011","unstructured":"Bojke L, Epstein D, Craig D, Rodgers M, Woolacott N, Yang H: Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis. Rheumatology (Oxford). 2011, 50 (Suppl 4): iv39-iv47.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"2010_CR18","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/annrheumdis-2012-eular.3245","volume":"71","author":"D Spurden","year":"2012","unstructured":"Spurden D, Orme ME, Mitchell S, Bird A: Systematic Review and network meta-analysis of biological therapy for the management of active psoriatic arthritis [SAT0298]. Ann Rheum Dis. 2012, 71 (3): 573-","journal-title":"Ann Rheum Dis"},{"key":"2010_CR19","unstructured":"NICE. NICE Guidelines Manual, Appendix D. http:\/\/www.nice.org.uk\/media\/633\/21\/The_guidelines_manual_2009_-_Appendix_D_Methodology_checklist_-_randomised_controlled_trials.pdf. 2009"},{"key":"2010_CR20","volume-title":"Updated guide to the methods and of technology appraisal","author":"National Institute for Health and Clinical Excellence (NICE)","year":"2008","unstructured":"National Institute for Health and Clinical Excellence (NICE): Updated guide to the methods and of technology appraisal. 2008, London: NICE"},{"key":"2010_CR21","volume-title":"NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-analysis of Randomised Controlled Trials","author":"S Dias","year":"2011","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades AE: NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-analysis of Randomised Controlled Trials. 2011"},{"issue":"4","key":"2010_CR22","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1191\/096228001678227794","volume":"10","author":"AJ Sutton","year":"2001","unstructured":"Sutton AJ, Abrams KR: Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res. 2001, 10 (4): 277-303. 10.1191\/096228001678227794.","journal-title":"Stat Methods Med Res"},{"key":"2010_CR23","volume-title":"Bayesian Approaches to Clinical Trials and Health Care Evaluation","author":"DJ Spiegelhalter","year":"2004","unstructured":"Spiegelhalter DJ, Abrams KR, Myles JP: Bayesian Approaches to Clinical Trials and Health Care Evaluation. 2004, Chichester, UK: Wiley"},{"key":"2010_CR24","unstructured":"Bayesian inference using Gibbs Sampling (BUGS): WinBUGS with DoodleBUGS version 1.4. Cambridge\/London, UK, http:\/\/www.mrc-bsu.cam.ac.uk\/bugs\/); 2003\u20137 [updated 2003\u20137; cited]; Available from: http:\/\/www.mrc-bsu.cam.ac.uk\/bugs\/"},{"issue":"7521","key":"2010_CR25","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","volume":"331","author":"DM Caldwell","year":"2005","unstructured":"Caldwell DM, Ades AE, Higgins JP: Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005, 331 (7521): 897-900. 10.1136\/bmj.331.7521.897.","journal-title":"BMJ"},{"issue":"9","key":"2010_CR26","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2165\/00019053-200826090-00006","volume":"26","author":"A Sutton","year":"2008","unstructured":"Sutton A, Ades AE, Cooper N, Abrams K: Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics. 2008, 26 (9): 753-67. 10.2165\/00019053-200826090-00006.","journal-title":"Pharmacoeconomics"},{"issue":"20","key":"2010_CR27","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1002\/sim.1875","volume":"23","author":"G Lu","year":"2004","unstructured":"Lu G, Ades AE: Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004, 23 (20): 3105-24. 10.1002\/sim.1875.","journal-title":"Stat Med"},{"issue":"6","key":"2010_CR28","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD: The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997, 50 (6): 683-91. 10.1016\/S0895-4356(97)00049-8.","journal-title":"J Clin Epidemiol"},{"issue":"26","key":"2010_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta9260","volume":"9","author":"AM Glenny","year":"2005","unstructured":"Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R: Indirect comparisons of competing interventions. Health Technol Assess. 2005, 9 (26): 1-134.","journal-title":"Health Technol Assess"},{"issue":"1","key":"2010_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00019053-200624010-00001","volume":"24","author":"AE Ades","year":"2006","unstructured":"Ades AE, Sculpher M, Sutton A, Abrams K, Cooper N, Welton N: Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics. 2006, 24 (1): 1-19. 10.2165\/00019053-200624010-00001.","journal-title":"Pharmacoeconomics"},{"key":"2010_CR31","volume-title":"United Kingdom Interim Life Tables 1980\u201382 to 2008\u201310","author":"Office for National Statistics","year":"2011","unstructured":"Office for National Statistics: United Kingdom Interim Life Tables 1980\u201382 to 2008\u201310. 2011, http:\/\/www.ons.gov.uk\/ons\/rel\/lifetables\/interim-life-tables\/2008-2010\/rft-ilt-uk-2008-2010.xls (Accessed: 03 December 2012)"},{"key":"2010_CR32","volume-title":"Haymarket Business Media","author":"MIMS","year":"2012","unstructured":"MIMS: Haymarket Business Media. 2012, London, UK"},{"key":"2010_CR33","volume-title":"Canterbury: Personal and Social Services Research Unit","author":"L Curtis","year":"2011","unstructured":"Curtis L, Unit costs of health and social care: Canterbury: Personal and Social Services Research Unit. 2011, Available at: http:\/\/www.pssru.ac.uk\/pdf\/uc\/uc2011\/uc2011.pdf. [Accessed 12 November 2012]"},{"key":"2010_CR34","volume-title":"BSR guideline for anti-TNFa therapy in psoriatic arthritis","author":"N McHugh","year":"2004","unstructured":"McHugh N, Chandler D, Griffiths C, Helliwell P, Lewis J, McInnes I: BSR guideline for anti-TNFa therapy in psoriatic arthritis. 2004, London: British Society for Rheumatology"},{"key":"2010_CR35","unstructured":"The Monthly Index of Medical Specialities (MIMS). http:\/\/www.mims.co.uk [Accessed: 12 November 2012]"},{"key":"2010_CR36","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1002\/art.10471","volume":"46","author":"G Kobelt","year":"2002","unstructured":"Kobelt G, J\u00f6nsson L, Lindgren P, Young AKE: Modelling the progression of rheumatoid arthritis:a two-country model to estimate costs to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum. 2002, 46: 2310-2319. 10.1002\/art.10471.","journal-title":"Arthritis Rheum"},{"key":"2010_CR37","volume-title":"Reference costs","author":"Department of Health","year":"2007","unstructured":"Department of Health: Reference costs. 2007, London: NHS, \u20132008"},{"key":"2010_CR38","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1046\/j.1365-2133.2002.04920.x","volume":"147","author":"M Hartman","year":"2003","unstructured":"Hartman M, Prins M, Swinkels OQ: Cost-effectiveness analysis of a psoriasis care instruction programme with dithranol compared with UVB phototherapy and inpatient dithranol treatment; Brit. J Dermatol. 2003, 147: 538-44.","journal-title":"J Dermatol"},{"key":"2010_CR39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","volume":"356","author":"PJ Mease","year":"2000","unstructured":"Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000, 356: 385-390. 10.1016\/S0140-6736(00)02530-7.","journal-title":"Lancet"},{"issue":"7","key":"2010_CR40","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/art.20335","volume":"50","author":"PJ Mease","year":"2004","unstructured":"Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P: Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004, 50 (7): 2264-2272. 10.1002\/art.20335. July 2004","journal-title":"Arthritis Rheum"},{"key":"2010_CR41","doi-asserted-by":"publisher","first-page":"c147","DOI":"10.1136\/bmj.c147","volume":"340","author":"W Sterry","year":"2010","unstructured":"Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD: Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 2010, 340: c147-10.1136\/bmj.c147.","journal-title":"BMJ"},{"issue":"4","key":"2010_CR42","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1136\/ard.2010.130864","volume":"70","author":"F Atzeni","year":"2011","unstructured":"Atzeni F, Boccassini L, Antivalle M, Salaffi F, Sarzi-Puttini P: Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study. Ann Rheum Dis. 2011, 70 (4): 712-4. 10.1136\/ard.2010.130864.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2010_CR43","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1136\/ard.2004.032268","volume":"64","author":"C Antoni","year":"2005","unstructured":"Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C: Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005, 64 (8): 1150-7. 10.1136\/ard.2004.032268.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2010_CR44","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/art.20967","volume":"52","author":"CE Antoni","year":"2005","unstructured":"Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U: Sustained Benefits of Infliximab Therapy for Dermatologic and Articular Manifestations of Psoriatic Arthritis. Results From the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum. 2005, 52 (4): 1227-1236. 10.1002\/art.20967. April 2005","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2010_CR45","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/ard.2011.152223","volume":"71","author":"A Baranauskaite","year":"2012","unstructured":"Baranauskaite A, Raffayova H, Kungurov N, Kubanova A, Venalis A, Helmle L: Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2012, 71 (4): 541-8. 10.1136\/ard.2011.152223.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2010_CR46","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jdermsci.2010.04.014","volume":"59","author":"H Torii","year":"2010","unstructured":"Torii H, Nakagawa H: Japanese Infliximab Study i. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci. 2010, 59 (1): 40-9. 10.1016\/j.jdermsci.2010.04.014.","journal-title":"J Dermatol Sci"},{"issue":"10","key":"2010_CR47","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH: Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005, 52 (10): 3279-89. 10.1002\/art.21306.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2010_CR48","first-page":"1040","volume":"34","author":"MC Genovese","year":"2007","unstructured":"Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA: Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol. 2007, 34 (5): 1040-50.","journal-title":"J Rheumatol"},{"issue":"8","key":"2010_CR49","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1136\/ard.2008.091389","volume":"68","author":"AWR van Kuijk","year":"2009","unstructured":"van Kuijk AWR, Gerlag DM, Vos K, Wolbink G, de Groot M, de Rie MA: A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. Ann Rheum Dis. 2009, 68 (8): 1303-9. 10.1136\/ard.2008.091389.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2010_CR50","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s10198-011-0335-x","volume":"13","author":"E Cummins","year":"2012","unstructured":"Cummins E, Asseburg C, Prasad M, Buchanan J, Punekar YS: Cost effectiveness of golimumab for the treatment of active psoriatic arthritis. Eur J Health Econ. 2012, 13 (6): 801-9. 10.1007\/s10198-011-0335-x.","journal-title":"Eur J Health Econ"},{"issue":"2","key":"2010_CR51","first-page":"282","volume":"30","author":"CA Pereda","year":"2012","unstructured":"Pereda CA, Nishishinya MB, Martinez Lopez JA, Carmona L: Efficacy and safety of DMARDs in psoriatic arthritis: a systematic review. Clin Exp Rheumatol. 2012, 30 (2): 282-9.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"2010_CR52","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/acr.21552","volume":"64","author":"PE Palominos","year":"2012","unstructured":"Palominos PE, Gaujoux-Viala C, Fautrel B, Dougados M, Gossec L: Clinical outcomes in psoriatic arthritis: A systematic literature review. Arthritis Care Res (Hoboken). 2012, 64 (3): 397-406. 10.1002\/acr.21552.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"2010_CR53","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3899\/jrheum.111233","volume":"39","author":"PS Helliwell","year":"2012","unstructured":"Helliwell PS, Fitzgerald O, Mease PJ: Development of composite measures for psoriatic arthritis: a report from the GRAPPA 2010 annual meeting. J Rheumatol. 2012, 39 (2): 398-403. 10.3899\/jrheum.111233.","journal-title":"J Rheumatol"},{"issue":"6","key":"2010_CR54","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1136\/annrheumdis-2012-201341","volume":"72","author":"PS Helliwell","year":"2013","unstructured":"Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K: The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013, 72 (6): 986-91. 10.1136\/annrheumdis-2012-201341.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2010_CR55","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/rheumatology\/ken320","volume":"47","author":"I Olivieri","year":"2008","unstructured":"Olivieri I, de Portu S, Salvarani C, Cauli A, Lubrano E, Spadaro A: The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology. 2008, 47 (11): 1664-70. 10.1093\/rheumatology\/ken320.","journal-title":"Rheumatology"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-15-26.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2474-15-26\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-15-26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-15-26.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T12:17:33Z","timestamp":1746101853000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/1471-2474-15-26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,20]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["2010"],"URL":"https:\/\/doi.org\/10.1186\/1471-2474-15-26","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,20]]},"assertion":[{"value":"23 May 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"26"}}